NovoCure Limited Ordinary Shares (NVCR) Dividend History

Company News

• NovoCure Surpasses Q1 Expectations

  NovoCure, a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, reported strong Q1 2025 results with revenue and GAAP earnings surpassing estimates. The company saw robust patient growth and progress in clinical trials, though challenges in gross margins remain.

  The Motley Fool
• Why NovoCure Stock Was Withering on Wednesday

  NovoCure, a cancer-focused biotech company, saw its stock price drop after an analyst reduced its price target, despite the change being relatively small. The market is hungry for good news from NovoCure, but as a biotech company, it requires time and resources to bring its products to market.

  The Motley Fool
• Why NovoCure Stock Was Winning Big This Week

  NovoCure, a cancer-targeting biotech company, reported positive results from a phase 3 clinical trial of its tumor treating fields (TTF) therapy. The therapy demonstrated a statistically significant improvement in survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. Analysts were encouraged by the results and raised their price targets on the stock.

  The Motley Fool
• Why NovoCure Stock Dived by 13% This Week

  NovoCure, a cancer-focused biotech company, saw its share price decline by over 13% over a holiday-shortened trading week due to a series of C-suite changes, including the departure of its long-serving CEO Asaf Danziger and COO Wilco Groenhuysen.

  The Motley Fool
• A Closer Look at 7 Analyst Recommendations For NovoCure

  7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 1 3 0 0 Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $25.29, accompanied by a high estimate of $42.00 and a low estimate of $17.00. This current average has decreased by 3.36% from the previous average price target of $26.17. Deciphering Analyst Ratings: An In-Depth Analysis A comprehensive examination of how financial experts perceive NovoCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Emily Bodnar HC Wainwright & Co. Maintains Neutral $22.00 $22.00 Emily Bodnar HC Wainwright & Co. Lowers Neutral $22.00 $24.00 Jason Bednar Piper Sandler Raises Overweight $28.00 $25.00 Larry Biegelsen Wells Fargo Lowers Overweight $42.00 $49.00 Emily Bodnar HC Wainwright & Co. Raises Neutral $24.00 $22.00 Jessica Fye JP Morgan Raises Neutral $17.00 $15.00 Emily Bodnar HC Wainwright & Co. Maintains Neutral $22.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, ...Full story available on Benzinga.com

  Benzinga